Compare Prospect Capital Corporation (PSEC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Repligen Corporation Common Stock — how do they compare? Prospect Capital Corporation trades at $1.58 (market cap $848.77M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 13.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 26.42% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Repligen Corporation Common Stock for 0 Days on average.
| PSEC | RGEN | |
|---|---|---|
Market Cap | $848.77M | $11.14B |
Volume | 7,084,485 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $3.05 | $194.57 |
52-Week Low | $1.60 | $102.87 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $2.67B | $11.02B |
Dividend Yield | 26.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.67, down 3.47% today, with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but negative revenue and net income in 2025. Recent earnings have consistently beaten expectations, though the company faces significant financial volatility with revenue swinging from $635M in 2022 to -$407M in 2025. Dividend distributions continue at $0.04 monthly, providing income appeal despite operational challenges.
The outlook remains cautious with analyst consensus leaning Hold (55%) amid financial instability. Key risks include persistent revenue volatility and negative cash flow. Upside potential exists from consistent earnings beats and deep valuation discounts, but investors should weigh income benefits against fundamental deterioration and bearish technical momentum.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
